Precipio Reports Data Access Incident, No Impact on Operations
Precipio reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The company said, "The incident was limited to its file storage server and did not impact any of Precipio's operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company's operations or finances. Upon detecting the activity, the Company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists to assist in the investigation and to help ensure the security of its systems. Precipio also took prompt steps to secure the environment, reset passwords company wide, and enhance monitoring and at this time, we are not seeing evidence of continued unauthorized access. While the investigation remains ongoing, current findings indicate that an unauthorized third party accessed and downloaded certain historical files within the customer service folder. Initial investigation shows that the majority of these files contained previously used operational procedures, temperature logs, vendor invoices and similar historical information which poses no risk or damage to the company. No patient Social Security numbers, addresses, or other patient financial information was included. Additionally, no company proprietary or financial data was included in the folders that were breached. We are pursuing a thorough investigation with top-tier cybersecurity partners, and although the review is ongoing, our current assessment strongly suggests that the incident was limited in scope and that our systems are stable. Precipio maintains a comprehensive cybersecurity insurance policy and expects that costs associated with the investigation, forensic analysis, and related response efforts will be covered in accordance with policy terms. Based on the information available at this time the company does not anticipate any material impact to its operations, customers, patient care, or to its shareholders as a result of this incident."
Trade with 70% Backtested Accuracy
Analyst Views on PRPO
About PRPO
About the author

AbbVie Launches New Immunology Drugs, Stock Up 31.6% Over Last Year
- New Drug Launch: AbbVie has successfully launched two new immunology drugs, Skyrizi and Rinvoq, which are expected to support revenue growth in the coming years following Humira's loss of exclusivity.
- Market Performance: AbbVie’s stock has risen 31.6% over the past year, significantly outperforming the 19.5% growth of the large-cap pharmaceuticals industry, indicating strong competitive positioning.
- Acquisition Strategy: The company has engaged in a series of acquisitions over the past few years to bolster its early-stage pipeline, aiming for long-term growth despite challenges from Humira's patent expiration.
- Diversified Product Line: AbbVie's oncology and neuroscience drugs are also contributing to revenue growth, further solidifying its position in the pharmaceutical industry.

Precipio Presents Findings from 895-Patient BCR::ABL1 Assay Study at ASH
- Study Findings Presentation: Precipio will present findings from a joint study with Memorial Sloan Kettering at the ASH meeting, involving 895 patient samples, demonstrating superior performance of the BCR::ABL1 assay, which enhances patient care and optimizes laboratory workflows.
- Significant Clinical Impact: The study shows that the BCR::ABL1 assay exhibits high concordance with two leading platforms, not only improving diagnostic accuracy but also potentially reducing cancer misdiagnosis rates, thereby enhancing treatment outcomes for patients.
- Industry Recognition: The poster presentation and results discussion scheduled for December 8 will further elevate Precipio's standing in the cancer diagnostics field, attracting increased attention and investment.
- Innovation-Driven Growth: Precipio's commitment to developing more efficient diagnostic products to address cancer misdiagnosis is reinforced by these study results, which will drive the company's expansion in the global laboratory market and strengthen its competitive edge.






